Shareholder Analysis
Significant Shareholdings
As at 28 February 2023, the Company’s issued share capital consists of 216,914,414 ordinary shares with a nominal value of 5p each (“Ordinary Shares”), each share having equal voting rights.
As at 28 February 2023 the Company’s major shareholders are:
Table: “Significant shareholdings”
| Shareholders | Percentage of shares held |
|---|---|
| Octopus Investments Limited | 12.65% |
| Canaccord Genuity Group Inc | 7.07% |
| Charles Stanley Group | 5.11% |
| Investec Group | 5.00% |
| BlackRock Inc | 4.38% |
| Invesco | 3.86% |
| Rathbone Plc | 3.63% |
| Groupama | 3.29% |
| AXA SA | 3.22% |
In accordance with the AIM Rules (Rule 26), insofar as the Company is aware as at 28 February 2023, the percentage of the Company’s issued share capital that is not in public hands is 14.34%. This percentage consists of the holdings of the directors’ beneficial holdings, the holdings of the AMS Trustee Company in respect of the Company’s Deferred Share Bonus Scheme, and the Company’s substantial shareholders. The Company’s free float is 85.66%.
Any corporate shareholders who wish to contact AMS, or provide information on their shareholding, can send an email to companysecretary@admedsol.com.